Gilead Sciences (NASDAQ: [[ticker:GILD]]) said today it has obtained a license from MicroDose Therapeutx to an inhalable small molecule drug for respiratory syncytial virus (RSV). Foster City-based Gilead agreed to make an upfront cash payment, research funding, milestone payments, and royalties on product sales to Monmouth Junction, NJ-based MicroDose. The dollar amount of the deal wasn’t disclosed. RSV infections are estimated to cause 125,000 infants to be hospitalized each year.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
